Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

56 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study.
Madsen CM, Varbo A, Nordestgaard BG. Madsen CM, et al. Among authors: varbo a. Eur Heart J. 2018 Feb 14;39(7):610-619. doi: 10.1093/eurheartj/ehx659. Eur Heart J. 2018. PMID: 29182745
During 456 057 person-years of follow-up, 1770 individuals experienced a major adverse cardiovascular event (MACE) and 734 experienced a myocardial infarction (MI). ...
During 456 057 person-years of follow-up, 1770 individuals experienced a major adverse cardiovascular event (MACE) and 734 experience …
TRIB1 and GCKR polymorphisms, lipid levels, and risk of ischemic heart disease in the general population.
Varbo A, Benn M, Tybjærg-Hansen A, Grande P, Nordestgaard BG. Varbo A, et al. Arterioscler Thromb Vasc Biol. 2011 Feb;31(2):451-7. doi: 10.1161/ATVBAHA.110.216333. Epub 2010 Nov 11. Arterioscler Thromb Vasc Biol. 2011. PMID: 21071687
Risk of IHD and MI was examined prospectively, cross-sectionally, and in a case-control study, and a metaanalysis was performed. ...
Risk of IHD and MI was examined prospectively, cross-sectionally, and in a case-control study, and a metaanalysis was performe …
Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population.
Varbo A, Nordestgaard BG, Tybjaerg-Hansen A, Schnohr P, Jensen GB, Benn M. Varbo A, et al. Ann Neurol. 2011 Apr;69(4):628-34. doi: 10.1002/ana.22384. Epub 2011 Feb 18. Ann Neurol. 2011. PMID: 21337605
METHODS: A total of 7,579 women and 6,372 men from the Copenhagen City Heart Study with measurements of nonfasting triglycerides and cholesterol at baseline in 1976-1978 were followed for up to 33 years; of these, 837 women and 837 men developed ischemic stroke during foll …
METHODS: A total of 7,579 women and 6,372 men from the Copenhagen City Heart Study with measurements of nonfasting triglycerides and …
Remnant cholesterol as a causal risk factor for ischemic heart disease.
Varbo A, Benn M, Tybjærg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG. Varbo A, et al. J Am Coll Cardiol. 2013 Jan 29;61(4):427-436. doi: 10.1016/j.jacc.2012.08.1026. Epub 2012 Dec 19. J Am Coll Cardiol. 2013. PMID: 23265341
The variants were used in a Mendelian randomization design. RESULTS: The causal odds ratio for a 1 mmol/l (39 mg/dl) genetic increase of nonfasting remnant cholesterol was 2.8 (95% confidence interval [CI]: 1.9 to 4.2), with a corresponding observational haza …
The variants were used in a Mendelian randomization design. RESULTS: The causal odds ratio for a 1 mmol/l (39 mg/dl) genetic i …
Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation.
Varbo A, Benn M, Tybjærg-Hansen A, Nordestgaard BG. Varbo A, et al. Circulation. 2013 Sep 17;128(12):1298-309. doi: 10.1161/CIRCULATIONAHA.113.003008. Epub 2013 Aug 7. Circulation. 2013. PMID: 23926208
A 1-mmol/L(39 mg/dL) higher level of nonfasting remnant cholesterol was associated observationally with a 37% (95% confidence interval, 35-39) higher C-reactive protein level and causally with a 28% (95% confidence interval, 10-48) higher level. For LDL chole
A 1-mmol/L(39 mg/dL) higher level of nonfasting remnant cholesterol was associated observationally with a 37% (95% confidence
Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment.
Varbo A, Benn M, Nordestgaard BG. Varbo A, et al. Pharmacol Ther. 2014 Mar;141(3):358-67. doi: 10.1016/j.pharmthera.2013.11.008. Epub 2013 Nov 26. Pharmacol Ther. 2014. PMID: 24287311 Review.
This review focuses on remnant cholesterol as a causal risk factor for ischemic heart disease (IHD), on its definition, measurement, atherogenicity, and levels in high risk patient groups; in addition, present and future pharmacological approaches to lowering remnant chole …
This review focuses on remnant cholesterol as a causal risk factor for ischemic heart disease (IHD), on its definition, measurement, …
Low nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study.
Thomsen M, Varbo A, Tybjærg-Hansen A, Nordestgaard BG. Thomsen M, et al. Among authors: varbo a. Clin Chem. 2014 May;60(5):737-46. doi: 10.1373/clinchem.2013.219881. Epub 2014 Jan 16. Clin Chem. 2014. PMID: 24436475
The odds ratio for a genetically derived 89-mg/dL (1-mmol/L) lower concentration in nonfasting triglycerides was 0.50 (0.30-0.82), with a corresponding observational hazard ratio of 0.87 (0.85-0.89). Also, the odds ratio for a genetically derived 50% lower co …
The odds ratio for a genetically derived 89-mg/dL (1-mmol/L) lower concentration in nonfasting triglycerides was 0.50 (0.30-0.82), wi …
Remnant cholesterol, low-density lipoprotein cholesterol, and blood pressure as mediators from obesity to ischemic heart disease.
Varbo A, Benn M, Smith GD, Timpson NJ, Tybjaerg-Hansen A, Nordestgaard BG. Varbo A, et al. Circ Res. 2015 Feb 13;116(4):665-73. doi: 10.1161/CIRCRESAHA.116.304846. Epub 2014 Nov 19. Circ Res. 2015. PMID: 25411050
METHODS AND RESULTS: Approximately 90 000 participants from Copenhagen were included in a Mendelian randomization design with mediation analyses. ...
METHODS AND RESULTS: Approximately 90 000 participants from Copenhagen were included in a Mendelian randomization design with mediati …
Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population.
Varbo A, Freiberg JJ, Nordestgaard BG. Varbo A, et al. Clin Chem. 2015 Mar;61(3):533-43. doi: 10.1373/clinchem.2014.234146. Epub 2015 Jan 20. Clin Chem. 2015. PMID: 25605681

Nonfasting remnant cholesterol concentrations were associated stepwise with all-cause mortality ranging from hazard ratio 1.0 (0.9-1.1) to 1.6 (1.4-1.9) (P < 0.001), whereas LDL cholesterol concentrations were associated with decreased all-cause mortality risk in a U-sh

Nonfasting remnant cholesterol concentrations were associated stepwise with all-cause mortality ranging from hazard ratio 1.0 (0.9-1.1) to 1 …
Elevated Lipoprotein(a) Does Not Cause Low-Grade Inflammation Despite Causal Association With Aortic Valve Stenosis and Myocardial Infarction: A Study of 100,578 Individuals from the General Population.
Langsted A, Varbo A, Kamstrup PR, Nordestgaard BG. Langsted A, et al. Among authors: varbo a. J Clin Endocrinol Metab. 2015 Jul;100(7):2690-9. doi: 10.1210/jc.2015-1096. Epub 2015 May 4. J Clin Endocrinol Metab. 2015. PMID: 25938632
For aortic valve stenosis, a 1-SD increase in lipoprotein(a) levels was associated observationally with a multifactorially adjusted hazard ratio of 1.23 (95% CI, 1.06-1.41), with corresponding causal risk ratios of 1.38 (1.23-1.55) based on LPA SNPs and of 1. …
For aortic valve stenosis, a 1-SD increase in lipoprotein(a) levels was associated observationally with a multifactoria …
56 results
Jump to page
Feedback